Raymond James Financial Inc. Takes $554,000 Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Raymond James Financial Inc. bought a new position in shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV) during the fourth quarter, HoldingsChannel reports. The fund bought 157,519 shares of the biopharmaceutical company’s stock, valued at approximately $554,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Sigma Planning Corp bought a new position in shares of Achieve Life Sciences in the 4th quarter worth about $37,000. SBI Securities Co. Ltd. bought a new stake in shares of Achieve Life Sciences in the 4th quarter worth $49,000. MetLife Investment Management LLC raised its holdings in shares of Achieve Life Sciences by 65.6% in the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 5,939 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Achieve Life Sciences by 74.8% during the fourth quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company’s stock valued at $70,000 after purchasing an additional 8,512 shares in the last quarter. Finally, Verition Fund Management LLC purchased a new position in Achieve Life Sciences during the third quarter worth about $113,000. Institutional investors and hedge funds own 33.52% of the company’s stock.

Insider Activity

In other Achieve Life Sciences news, CFO Mark K. Oki acquired 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $2.89 per share, with a total value of $28,900.00. Following the transaction, the chief financial officer now owns 10,000 shares of the company’s stock, valued at $28,900. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.00% of the company’s stock.

Achieve Life Sciences Price Performance

Shares of NASDAQ ACHV opened at $2.22 on Tuesday. The firm has a market cap of $77.00 million, a price-to-earnings ratio of -1.96 and a beta of 1.59. The stock has a fifty day simple moving average of $2.99 and a two-hundred day simple moving average of $3.82. The company has a current ratio of 6.78, a quick ratio of 6.78 and a debt-to-equity ratio of 0.31. Achieve Life Sciences, Inc. has a 1-year low of $2.04 and a 1-year high of $5.59.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.06). Analysts anticipate that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current year.

Achieve Life Sciences Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.